Adynxx (OTCMKTS:ADYX – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.
Valuation & Earnings
This table compares Adynxx and NovoCure”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Adynxx | N/A | N/A | N/A | N/A | N/A |
NovoCure | $509.34 million | 3.42 | -$207.04 million | ($1.40) | -11.51 |
Adynxx has higher earnings, but lower revenue than NovoCure.
Analyst Recommendations
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Adynxx | 0 | 0 | 0 | 0 | 0.00 |
NovoCure | 0 | 2 | 4 | 0 | 2.67 |
NovoCure has a consensus price target of $26.17, suggesting a potential upside of 62.42%. Given NovoCure’s stronger consensus rating and higher probable upside, analysts plainly believe NovoCure is more favorable than Adynxx.
Insider and Institutional Ownership
84.6% of NovoCure shares are owned by institutional investors. 17.4% of Adynxx shares are owned by company insiders. Comparatively, 6.3% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Adynxx and NovoCure’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Adynxx | N/A | N/A | N/A |
NovoCure | -25.93% | -41.48% | -12.74% |
Summary
NovoCure beats Adynxx on 5 of the 9 factors compared between the two stocks.
About Adynxx
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Receive News & Ratings for Adynxx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adynxx and related companies with MarketBeat.com's FREE daily email newsletter.